Next Science Ltd Total Assets
Next Science Ltd total assets. Based on the latest financial reports, Next Science Ltd (NXS) holds total assets worth AU$9.46 Million AUD (≈ $6.69 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Next Science Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Next Science Ltd (2016–2024)
Total assets of Next Science Ltd from 2016 to 2024. This chart illustrates how Next Science Ltd's total assets have evolved over time, based on quarterly financial data. See NXS live share price for real-time trading data and today's change.
Next Science Ltd - Asset Composition Analysis
Next Science Ltd Total Assets Breakdown (December 2024)
Next Science Ltd total assets breakdown as of December 2024. Next Science Ltd's total assets of AU$9.46 Million consist of 65.7% current assets and 34.3% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 18.2% |
| Accounts Receivable | AU$3.34 Million | 36.2% |
| Inventory | AU$726.24K | 7.9% |
| Property, Plant & Equipment | AU$1.07 Million | 11.6% |
| Intangible Assets | AU$828.15K | 9.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Next Science Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore NXS net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Next Science Ltd's current assets represent 65.7% of total assets in 2024, an increase from 58.0% in 2016.
- Cash Position: Cash and equivalents constituted 18.2% of total assets in 2024, down from 49.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, a decrease from 25.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 36.2% of total assets.
Next Science Ltd Competitors by Total Assets
Key competitors of Next Science Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Porton Fine Chemicals Ltd
SHE:300363
|
China | CN¥8.58 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
India | Rs135.21 Billion |
Next Science Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 2.17 | 7.25 |
| Quick Ratio | 1.25 | 1.96 | 7.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$1.82 Million | AU$4.41 Million | AU$11.03 Million |
Next Science Ltd - Advanced Valuation Insights
This section examines the relationship between Next Science Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.18 |
| Latest Market Cap to Assets Ratio | 3.26 |
| Asset Growth Rate (YoY) | -48.5% |
| Total Assets | AU$9.21 Million |
| Market Capitalization | $30.02 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Next Science Ltd's assets at a significant premium (3.26x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Next Science Ltd's assets decreased by 48.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Next Science Ltd (2016–2024)
The table below shows the annual total assets of Next Science Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AU$9.21 Million ≈ $6.52 Million |
-48.53% |
| 2023-12-31 | AU$17.90 Million ≈ $12.67 Million |
-2.57% |
| 2022-12-31 | AU$18.37 Million ≈ $13.00 Million |
+34.35% |
| 2021-12-31 | AU$13.67 Million ≈ $9.68 Million |
-41.79% |
| 2020-12-31 | AU$23.49 Million ≈ $16.62 Million |
+3.44% |
| 2019-12-31 | AU$22.71 Million ≈ $16.07 Million |
-13.24% |
| 2018-12-31 | AU$26.18 Million ≈ $18.52 Million |
+527.76% |
| 2017-12-31 | AU$4.17 Million ≈ $2.95 Million |
+162.54% |
| 2016-12-31 | AU$1.59 Million ≈ $1.12 Million |
-- |
About Next Science Ltd
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides woun… Read more